Alterations in fibrosis-related gene expression and proteomic expression profile in rat hepatic stellate cells exposed to the cocktail

World Chinese Journal of Digestology

Volumn 19, Issue 17, 2011, Pages 1780-1784

  Liao, Ming ^a   Mo, Cai Feng ^b   Zhou, Yi ^c   He, Min ^a   Zhuo, Lang ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b GUILIN MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

Author keywords

Cocktail therapy; Gene expression; Hepatic stellate cells; Protein expression

Indexed keywords

ANTIFIBROTIC AGENT; GELATINASE A; PROTEOME; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG MIXTURE; GENE EXPRESSION PROFILING; LIVER FIBROSIS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; RAT; STELLATE CELL; UPREGULATION;

EID: 79960375239     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v19.i17.1780     Document Type: Article

References (36)

1. Weng H, Mertens PR, Gressner AM, Dooley S. IFNgamma abrogates profibrogenic TGF-beta signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatol 2007; 46: 295-303
2. Son G, Iimuro Y, Seki E, Hirano T, Kaneda Y, Fujimoto J. Selective inactivation of NF-kappaB in the liver using NF-kappaB decoy suppresses CCl4-induced liver injury and fibrosis. Am J Physiol Gastrointest Liver Physiol 2007; 293: G631-G639
3. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48: 322-335
4. Iimuro Y, Brenner DA. Matrix metalloproteinase gene delivery for liver fibrosis. Pharm Res 2008; 25: 249-258
5. Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, Ehnert S, Ueberham E, Gebhardt R, Kanzler S, Geier A, Breitkopf K, Weng H, Mertens PR. Hepatocytespecific Smad7 expression attenuates TGF-betamediated fibrogenesis and protects against liver damage. Gastroenterology 2008; 135: 642-659
6. Inagaki Y, Higashi K, Kushida M, Hong YY, Nakao S, Higashiyama R, Moro T, Itoh J, Mikami T, Kimura T, Shiota G, Kuwabara I, Okazaki I. Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7. Gastroenterology 2008; 134: 1180-1190
7. Comporti M, Signorini C, Arezzini B, Vecchio D, Monaco B, Gardi C. Isoprostanes and hepatic fibrosis. Mol Aspects Med 2008; 29: 43-49
8. Dumont JM, Maignan MF, Janin B, Herbage D, Perrissoud D. Effect of malotilate on chronic liver injury induced by carbon tetrachloride in the rat. J Hepatol 1986; 3: 260-268
9. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218
10. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669
11. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999; 96: 12719-12724
12. Préaux AM, Mallat A, Rosenbaum J, Zafrani ES, Mavier P. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast- like cells. Hepatology 1997; 26: 315-322
13. Chinese Sources.
14. Chinese Sources.
15. Giannelli G, Antonaci S. Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection. Histol Histopathol 2005; 20: 939-944
16. Friedman SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 98-105
17. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta 2006; 364: 33-60
18. Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner AM. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 2000; 31: 1094-1106
19. Nakamura T, Ueno T, Sakamoto M, Sakata R, Torimura T, Hashimoto O, Ueno H, Sata M. Suppression of transforming growth factor-beta results in upregulation of transcription of regeneration factors after chronic liver injury. J Hepatol 2004; 41: 974-982
20. Chinese Sources.
21. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7: d793-d807
22. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 1995; 92: 2572-2576
23. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, zum Büschenfelde KH, Blessing M. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 1999; 276: G1059-G1068
24. Schnur J, Oláh J, Szepesi A, Nagy P, Thorgeirsson SS. Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol 2004; 16: 127-133
25. Chinese Sources.
26. Chinese Sources.
27. Albanis E, Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 2001; 5: 315-334, 5-6
28. Safadi R, Friedman SL. Hepatic fibrosis--role of hepatic stellate cell activation. MedGenMed 2002; 4: 27
29. Chinese Sources.
30. Chinese Sources.
31. Jia JD, Bauer M, Cho JJ, Ruehl M, Milani S, Boigk G, Riecken EO, Schuppan D. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 2001; 35: 392-398
32. Chinese Sources.
33. Chinese Sources.
34. Chinese Sources.
35. Ninomiya T, Yoon S, Nagano H, Kumon Y, Seo Y, Kasuga M, Yano Y, Nakaji M, Hayashi Y. Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenetic effect of interferon-alfa in chronic hepatitis C patients. Intervirology 2001; 44: 227-231
36. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, Schiraldi O, Antonaci S. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002; 97: 425-431